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The authors revise the concept of anaplastic large cell lymphoma (ALCL) in the light of the recently updated WHO classiﬁcation
of Tumors of Hematopoietic and Lymphoid Tissues both on biological and clinical grounds. The main histological ﬁndings are
illustrated with special reference to the cytological spectrum that is indeed characteristic of the tumor. The phenotype is reported
indetail:theexpressionoftheALKproteinaswellasthechromosomalabnormalitiesisdiscussedwiththeirpotentialpathogenetic
implications. The clinical features of ALCL are presented by underlining the diﬀerence in terms of response to therapy and survival
between the ALK-positive and ALK-negative forms. Finally, the biological rationale for potential innovative targeted therapies is
presented.
1.Introduction
Anaplastic large cell lymphoma (ALCL) is a peripheral
T-cell-derived malignancy, representing around 2%-3% of
all lymphoid neoplasms, according to the World Health
Organization (WHO) estimates [1, 2]. Originally described
by Stein et al. in 1985 [3], it has undergone a series of
revisions, which have led to a more reﬁned and restrictive
deﬁnition of the process [1, 2, 4, 5]. In particular, two
diﬀerent entities are recognized as systemic forms, the ALK+
andALK− ALCL[1,2,6],ongeneticandclinicalfeatures,the
ﬁrst one being characterized by the deregulated expression
of chimeric proteins expressing the intracytoplasmic domain
of the anaplastic lymphoma kinase (ALK)g e n e .N o t e w o r t h y ,
in the last edition of the WHO classiﬁcation, ALK− ALCL
was regarded only as a provisional entity [1, 2]. However,
emerging evidences suggest the existence of two real tumors
[7]. On the other hand, diﬀerently from what initially
reported by Stein et al. [3], the cutaneous variant was
recognized as a diﬀerent disease [8].
Primary systemic ALCL has a peak incidence in child-
hood, accounting for approximately 40% of NHL cases
diagnosed in pediatric patients [9], whereas it accounts for
<5% of NHL in adults [1, 2, 10] ,a n di ti ss e e nm o s t l yi n
males.Patients present withstageIII toIVdisease, oftenwith
multiple extranodal sites of involvement [1, 2, 11, 12].
Inthisarticle,theauthors,basedontheirownexperience
and the most recent literature, review the main pathobiolog-
ical features of systemic ALCL, by focusing on the molecular
abnormalities representing potential targets for innovative
therapies.
2.Morphology
According to the WHO classiﬁcation, ALCL is not sustained
by a unique histotype but actually includes ﬁve morpho-
logic variants (common, giant cell-rich, lympho-histiocytic,2 Advances in Hematology
small-cell type, and Hodgkin-like) [1, 2, 13, 14]. Indeed,
common ALCL corresponds to the description of the tumor
given by Stein and coworkers in 1985 [3].
Allmorphologicalvariantsarecharacterizedbyavariable
proportion of large hallmark cells with eccentric horse-shoe
or kidney-shaped nuclei, often with eosinophilic region near
the nucleus (Figure 1) .T h eg i a n tc e l l - r i c ht y p ei sc h a r a c t e r -
ized by several multinucleated elements, often provided with
Reed-Sternberg-like features and prominent intrasinusoidal
diﬀusion [1, 5, 15, 16]. The small and lympho-histiocytic
variantsdisplayamarkedvariabilityoftheneoplasticcellsize
that ranges from small to large. The main diﬀerence between
the two forms is an aboundant reactive histiocytosis with
eccentric nucli in the latter [1, 2, 13, 17–19]. Such a reactive
population tends to obscure the neoplastic component and
can lead to a misdiagnosis of hyperimmune reaction [1, 2,
13, 17, 18, 20]. Interestingly, transition from one histotype to
the other is at times recorded within the same node (mixed
variant) or in diﬀerent nodes taken from the same patient
at the time of diagnosis or in relapse: these modiﬁcations
might correspond to intraclonal modulation or diﬀerent
interaction between the tumor and microenvironment [13,
21]. Further variants have been reported in the literature:
signet-ring cell-like, sarcomatoid, epitheliod cell-rich, and
eosinophilic-rich [13, 22, 23]. They are much rarer than
the previous ones and may indeed represent a diagnostic
challenge. Finally, the so-called ALCL of the Hodgkin-
like type deserves special attention [24]. It was originally
described as a form of the tumor, presenting in young people
with a bulky mediastinal mass and consisting of anaplastic
cells arranged in nodules surrounded by sclerotic bands, as
seen in nodular sclerosing Hodgkin’s lymphoma (NSHL)
[24]. Following the introduction of the REAL Classiﬁcation
[5], which regarded it as a provisional entity, such diagnosis
was by no means also applied to cases of aggressive HL
that could not be easily diﬀerentiated from ALCL, both
on morphologic and on phenotypic grounds [5]. This led
to a diﬀuse skepticism on the existence of such variant: it
was considered an undeﬁned group more than an entity.
However, bona ﬁde examples of ALCL of the Hodgkin’s-like
type can be encountered. These are characterized by ALK
protein-expression, homogeneous CD30-positivity, lack of
CD15 and B-cell activator protein (BSAP), possible T-cell
antigen expression, and variable positivity for the leukocyte
common antigen/CD45 and epithelial membrane antigen
(EMA) (see below).
Only basing on morphology and phenotype, the ALK−
ALCL is not reproducibly distinguishable from the ALK+
variant. The two neoplastic proliferations show, in fact, a
similar morphological spectrum, although the small cell
variantisnotrecognizedinALK− ALCL.Theneoplasticcells,
in ALK− ALCL tend to be larger and more pleomorphic,
with higher nuclear/cytoplasmatic ratio than those seen in
classical ALK+ cases. This feature may suggest a diagnosis
of peripheral T-cell lymphoma not otherwise speciﬁed
(PTCL/NOS), but in the latter disorder, small-medium-
sized lymphocytes are often admixed with a morphological
homogeneous neoplastic cell proliferation and sheet-like or
sinus pattern of inﬁltration typical of ALCL is absent. Lastly,
ALK− ALCL must be distinguished from primary cutaneous
ALCL which can have a similar phenotype and morphology.
Thus, the clinical correlation with staging is golden rule in
those cases because primary cutaneous ALCL has a much
better prognosis than ALK− ALCL.
3. Phenotype
Neoplastic cells of ALCL carry a distinctive phenotypic
proﬁle irrespective of the histotype [1, 2, 15, 25]. They
regularly express CD30 [1–3, 26]( Figure 1) ,ag l y c o p r o t e i n
of 120kD carried by lymphoid elements following activation
and formed by three distinct domains (intracytoplasmic,
transmembranic, and external) [3, 26]. It is encoded by a
gene located at 1p36, whose activity is modulated by the
number of ATCC-repeats in the 5  region of the promoter,
and represents a member of the receptor superfamily of
tumor necrosis factor (TNF) [26]. Notably, CD30 overex-
pression has been reported to induce constitutive NF-κB
activation [27, 28]. As expected, the CD30 ligand (CD30L)
belongs to a group of molecules, which show homologies
withTNF.TheexternaldomainofCD30issteadilycleavedby
a metalloproteinase so that it can be detected and measured
in the serum [29]. At immunohistochemical analysis in both
in paraﬃn and frozen sections, the antibodies against CD30
producediﬀerenttypesofpositivity:membrane-bound,dot-
like in the Golgi area (corresponding to the accumulation
of the 90kD proteic precursor), and diﬀuse [26]. The ﬁrst
two patterns are exclusive to lymphoid elements with the
exception of embryonic carcinoma [26], while the third
one can occur in a variety of malignant tumors other than
lymphomas,includingpancreascarcinoma,naso-pharyngeal
undiﬀerentiated carcinoma, mesothelioma, and malignant
melanoma [26]. Therefore, the immunophenotypic diagno-
sis of ALCL should always be based on the application of
a panel of antibodies, including reagents anticytokeratins,
melanoma-associated antigens, CEA, and PLAP [1, 2]. In
60%–70% of cases, ALCL carries the epithelial membrane
antigen (EMA) (Figure 1) :t h i sm o l e c u l ei sm o r ee a s i l y
detected in Bouin-ﬁxed samples [13, 30]. CD3 expression
is appreciated in about half cases: it usually occurs at the
cytoplasmic level as expected in activated cells [13, 31].
All T-cell associated antigens should be explored, as CD3
negative tumors may carry CD2, CD5, and/or CD7 [13,
15, 31–33]. The expression of CD4 and CD8 is variable
[13, 15]. Positivity for TIA-1, granzyme B, and perforin
is recorded in about 85% of instances (Figure 1). NK-
antigens have at times been detected, in both spontaneous
and experimental tumors [34, 35]. About 20% of ALCLs
lack CD45 and/or express CD15 [13]( Figure 1). Notably,
BSAP (i.e., the PAX5 gene product) is absent [36]: its search
represents a very useful tool for the diﬀerentiation of ALCL
from common HL and DLBCL, which are both BSAP-
positive [36]. The recent development of antibodies against
the anaplastic large cell lymphoma kinase (ALK) has further
reﬁned the immunohistochemical analysis of ALCL [13, 15,
17, 37]( Figure 1). In fact, expression of this molecule does
characteristically occur in cases carrying translocations that
involve the corresponding gene (see below) [13, 15, 17, 37]Advances in Hematology 3
GM-1
(a)
GM-2
(b)
CD30
(c)
CD45
(d)
Perf
(e)
EMA
(f)
ALK
(g)
ALK
(h)
Figure 1: Morphological and immunophenotypical features of ALCL. At morphology (GM), a variable amount of hallmark cells can be
identiﬁed, the phenotype being typically CD30+, and possibly CD45−,E M A +, and Perforin (Perf)+.I nA L K + cases, ALK staining more
frequently interests both nucleus and cytoplasm, being associated with NMP1/ALK translocation. However, diﬀerent transcripts may
determine an isolated cytoplasmic or membranous staining (see insets; refer to Table 1 for details).
(Table 1). In principle, the most common t(2;5) causes
strong positivity of the neoplastic cells at the cytoplasmic
and nuclear levels, while the other translocations produce
accumulationoftheproteininthecytoplasm.Thesediﬀerent
staining patterns correspond to over-expression of the ALK
gene product: they bear diagnostic relevance, since ALK is
detected neither in normal lymphocytes nor in HL [17, 38].
Of note, such kinase has been identiﬁed in some lymphoid4 Advances in Hematology
Table 1: Main translocation involving ALK recorded in anaplastic large cell lymphoma.
Chromosomal translocation Partner gene Fusion gene Frequency (5) ALK IHC detection
t(2;5)(p23;q35) NPM1 NPM1/ALK 75–80 Cytoplasmic/nuclear
t(1;2)(q25;p23) TMP3 TMP3/ALK 12–18 Cytoplasmic
inv(2) ATIC ATIC/ALK 2C y t o p l a s m i c
t(2;3)(p23;q21) TGF TGF/ALK 2C y t o p l a s m i c
t(2;17)(p23;q23) CLTL CLTL/ALK 2C y t o p l a s m i c
t(2;17)(p23;q25) ALO17 ALO17/ALK <1C y t o p l a s m i c
t(2;19)(p23;p13) TPM4 TPM4/ALK <1C y t o p l a s m i c
t(2;22)(p23;q11.2) MYH9 MYH9/ALK <1C y t o p l a s m i c
t(2;X)(p23;q11-12) MSN MSN/ALK <1M e m b r a n o u s
NPM1: nucleophosmin; ALK: anaplastic lymphoma kinase; TPM3:t r o p o m y o s i n3 ;ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltrans-
ferase/IMP cyclohydrolase; TGF:T R K - f u s e dg e n e ;CLTL: Clathrin heavy chainlike 1; ALO17: ALK lymphoma oligomerization partner on chromosome 17;
TPM4:t r o p o m y o s i n4 ;MYH9: Nonmuscle myosin heavy chain; MSN: moesin; IHC: immunohistochemistry.
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Figure 2: Schematic representation of ALK signalling. In particular, ALK signalling promotes tumor cell proliferation and survival via
STAT3, RAS/ERK, and AKT/mTOR pathways. Noteworthy, the blockage of the signalling was demonstrated to have signiﬁcant antitumor
activity in experimental models of ALK+ ALCL.
and nonlymphoid neoplasms that have nothing in common
with ALCL [38]. In particular, it can occur—more often
at the cytoplasmic level—in B-plasmablastic lymphomas
bearing a distinctive phenotype (ALK+, CD138+,E M A +,
IgA+/−, Bcl-2 protein+/−,C D 4 −/+, CD57−/+, CD20−,C D 3 −,
and CD30−): like ALCL, these tumors do also carry cyto-
genetic abnormalities involving the ALK gene [38]. Among
nonhaematopoietic neoplasms, ALK positivity is found in
inﬂammatory myoﬁbroblastic tumour (IMT) and some
neuroblastomas and rhabdomyosarcomas and carcinomas
[39, 40]. Interestingly, it has been shown that ALK has
immunogenic properties, thus causing the production of
antibodies that can be easily detected in the serum and
might be relevant to the relatively good prognosis of ALK+
ALCL [41]. These immunogenic properties should be taken
into account for two additional reasons: (1) they might
be employed for vaccination strategies [42] and (2) they
might cause extensive tumor destruction, hypocellularity,
and oedema of the aﬀected nodes, thus mimicking an
inﬂammatory lesion [43]. Notably, ALK expression is felt
t op l a yar e l e v a n tr o l ei nt h ep r o c e s so fl y m p h o m a g e n e s i s ,
as suggested by experimental data [44–46]. In this respect,
experimental and in vivo studies have provided evidence that
the chimeric protein NPM/ALK secondary to t(2;5) causes
profound deregulation of cell kinetics. In fact, it determines
phosphorylation of JAK3 and/or direct STAT3 activation:
the later induces expression of TIMP1 and Bcl-XL and Bcl-
A2 that in turn with increased activated caspase-3 levels
contributes to the activation of the antiapoptotic pathway
[46]( Figure 2). In addition, the NPM/ALK chimeric proteinAdvances in Hematology 5
facilitates proliferation via activation of a series of factors,
including PLC-γ, type IA phosphoinositide 3-kinase, Src-
kinases, AKT, and FOXO3a [23]( Figure 2). Interestingly, the
above mentioned cell-kinetic alterations are not observed to
the same extent in many ALK− ALCLs, a fact that further
supports the distinction of ALK-positive and negative cases.
In line with this, the diﬀerent expression of the lymphocyte
speciﬁc protein (LSP1) detected in all ALK+ ALCLs and only
25% of the negative ones [47]. Conversely, expression of
retinoblastoma protein and survivin can occur in both ALK+
and ALK− ALCLs, in any case representing independent
unfavorable prognostic indicators [48, 49].
Finally, the search for Epstein-Barr virus (EBV) is
negativeinmostifnotallALCLsbothbyinsituhybridization
(ISH) by and immunohistochemistry: such negativity is
regarded as one of the distinguishing features between
ALCL and HL in controversial cases [50]. Recently, however,
occasional ALK+ ALCLs showing EBV integration in their
genome have been reported: they occurred in patients with
a previous history of solid organ transplant [51].
4.MolecularGenetics
The t(2;5)(p23;q35) was originally described in examples
of malignant histiocytosis (MH) [52]. These actually rep-
resented ALCL cases diagnosed according to dated criteria.
In fact, it quickly became evident that such transloca-
tions characteristically occurred in ALCL [53–56]. At the
beginning, the real incidence of the phenomenon was
uncertain: in fact, the need for fresh or frozen material
for cytogenetic studies or Southern blot analysis prevented
its systemic search. In principle, the aberration produced
the development of a hybrid gene, formed by the segment
of the ALK gene encoding for the transmembrane portion
of the corresponding kinase and the NH2-terminal region
of the NPM1 gene [38, 57]. Under physiologic conditions,
the latter encodes for nucleophosmin, that is, a shuttle-
protein that undergoes dimerization in the cytoplasm and
subsequently moves to the nucleus [58]. Thanks to the
production of highly speciﬁc (polyclonal and monoclonal)
antibodies against the transmembrane domain of the ALK
protein, as well as the NH2- and COOH-terminal regions
of NPM, the identiﬁcation of the chimeric NPM/ALK
protein (also termed p80 because of its molecular weight)
became easily feasible in routine (formalin-ﬁxed, paraﬃn-
embedded) samples [17, 37, 59]. The resulting assessment
demonstrated that the large majority of cases diagnosed as
ALCL according to the REAL/WHO Classiﬁcation do indeed
carry t(2;5) [55, 60]. The staining produced by the antiALK
antibodies is typically cytoplasmic and nuclear: this is due
to the fact that the NPM/ALK protein forms heterodimers
with normal NPM and—like normal NPM homodimers—
is shuttled to the nucleus [37, 60, 61]( Figure 1). Unexpect-
edly, the broad application of the monoclonal antibodies
ALK1 and ALKc revealed that about 10% of ALK+ ALCLs
showed an immunohistochemical reactivity conﬁned to the
cytoplasm. This was concomitant with the detection of a
series of additional translocations (commonly called variant
translocations), all involving the ALK gene, but leading to
the formation of a chimeric gene with partners other than
NPM1 [38, 62]( Figure 1). The derived hybrid proteins—all
leading to deregulated expression of ALK fusion proteins—
are more often under oligomerization but have not shuttling
properties, thus remaining conﬁned to the cytoplasm [38].
The most relevant of these variant translocations are listed in
Table 1.
Interestingly, one of these variants, t(2;17)(p23;q23),
is also observed in IMT as well as in B-plasmablastic
lymphoma [63, 64], while t(1;2)(q25;p23), t(2;19)(p23;p13),
and t(2;11;2)(p23;p15;q31) are detected more frequently in
I M Tt h a ni nA L C L[ 63]. Conversely, with the exception of
two studies, which results could not be reproduced in other
l a b s ,n e i t h e rA L Kp r o t e i nd e t e c t i o nn o rt ( 2 ; 5 )o rv a r i a n t
t r a n s l o c a t i o n sh a v eb e e nd e t e c t e di nH L[ 65].
Recently, by using a comparative genomic hybridization
(CGH) platform, Salaverria et al. [66] identiﬁed chromoso-
mal imbalances in 58% of ALK+ ALCL and in 65% of ALK−
cases, within a cohort of 74 cases (43 ALK+ and 31 ALK−,
resp.). Importantly, ALCL carrying NPM1-ALK or other
translocations involving ALK showed a similar proﬁle of
genetic alterations. In particular, recurrent gains of 17p and
17q24andlossesof4q13-q21and11q14werefoundinALK+
ALCL. On the other hand, gains of 1q and 6p21 were more
frequently observed in ALK− forms [66]. Thus, CGH data
conﬁrmed that ALK+ and ALK− ALCL are diﬀerent genetic
diseases, though few recurrent chromosomal imbalances
were found in both types of tumors (gains of 7 and 6q
and 13q losses), conﬁrming that all ALCLs probably share
common pathogenetic events (see below) [67, 68].
4.1. Gene Expression Proﬁling. Regarding gene expression
proﬁling (GEP), Thompson et al. [67] initially demonstrated
the ability of GEP to correctly distinguish between ALK+ and
ALK− ALCL based on the analysis of their transcriptome.
Importantly, in this study it was also suggested that some
pathogenetic mechanisms might be shared by these two
entities, based on the common expression of certain genes
in both ALK+ and ALK− cases.
Subsequently, the study by Lamant et al. [69]c o n ﬁ r m e d
that the diﬀerent morphological variants of ALCL (common
type,smallcell,and“mixed”variants)couldbedistinguished
based on the expression of speciﬁc genes. Moreover, it was
shown that ALK+ and ALK− ALCL have diﬀerent molecular
signatures. Speciﬁcally, within the molecular signature of
ALK+ ALCL BCL6, CEBPB, SERPINA1, and PTPN12 were
found to be overexpressed, some of these data being further
validated by immunohistochemistry on tissue microarrays.
Conversely, ALK− ALCLs were found to overexpress CCR7,
CNTFR, IL22, and IL21. Overall, this study strongly sup-
ported the concept that ALK+ and ALK− ALCL are diﬀerent
entities but did not provide novel information as far as the
molecular pathogenesis of ALK− ALCL was concerned.
Our group then included some ALCL in a GEP study
on PTCLs [68]. Interestingly, we found that ALCL can be
roughly distinguished from other PTCLs irrespectively of the
ALK status, conﬁrming the idea of common pathogenetic
events. Finally, additional important information has been
then oﬀered by Piva et al. [70] .I nt h i ss t u d y ,w eh a v em a i n l y6 Advances in Hematology
focused on the molecular pathogenesis of ALCL but also
established the relationship between ALCL and PTCL/NOS.
In particular, we showed that ALCLs are molecularly distinct
from PTCL/NOS. Signiﬁcantly, a predictive analysis allowed
identiﬁcation of 34 probe sets capable of distinguishing
ALCL from other T-NHL, suggesting that ALCLs share
importantbiopathologicalfeatures.Furthermore,itwaspos-
sible to clearly diﬀerentiate ALK+ and ALK− cases according
to their GEPs, based on the expression of selected genes,
including GAS1, an ALK dependent molecule [7]. Finally,
we demonstrated the strong biological relevance of the
ALK/STAT3 signaling in characterizing the global molecular
proﬁle of ALK+ ALCL [70].
More recently, Eckerle et al. [33] studied isolated cells
from ALCL cases. Interestingly, the analysis supported the
derivation of ALCL from activated T cells, though it was not
possible to identify a speciﬁc counterpart [33]. Surprisingly,
the authors found that only few genes were diﬀerentially
expressed between systemic and cutaneous ALCL despite
their diﬀerent clinical behavior, and between ALK− ALCL
and classical Hodgkin lymphoma, despite their diﬀerent
cellular origin [33].
4.2. Besides the NPM-ALK Chimera. Besides the NPM-ALK
chimera several other fusions of ALK have been described
in lymphoid neoplasms and more recently in epithelial
cancers. Among them, TFG gene (TFG-ALKS (short), TFG-
ALKL (long), and TFG-ALKXL (extra long)) have been
described [38]. In these translocations, diﬀerent length
fragments of the 5
  TFG region, all of them containing
the TFG coiled-coil oligomerization domain, are fused with
the intracytoplasmic domain of ALK, which drives the
constitutive ALK kinase activation. Since the TFG-ALK
fusion proteins lack nuclear localization, signals are mainly
conﬁned to the cytoplasmic compartment. Analogously,
the translocation t(1;2)(p23;q21) leads to translation of an
another cytoplasmic ALK fusion protein in which the NH-2
terminus region of TPM3 is linked to the intracytoplasmic
domain of ALK. ALK fusions also occur with TPM4, a
homolog of TPM3, and both TPM3- and TPM4-ALK
proteinsleadtotheconstitutiveautophosphorylationofALK
asaresultofhomodimerizationthroughtheTPMcoiled-coil
domains [38].
ATIC, CLTCL and MSN-ALK are also nonnuclear ALK
fusion chimeras. In ATIC-ALK, the 5-aminoimidazole-4-
carboxamideribonucleotideformyltransferase/IMPcyclohy-
drolase (ATIC) gene, located within chromosome 2, which
catalyzes steps of de novo purine nucleotide biosynthesis,
is fused to ALK as a result of cryptic inversion inv(2)
9p23q35 [38]. ALK can be fused to the CLTCL (clathrin
heavy polypeptide-like) gene (17q23) and CLTCL-ALK
proteins display a typical cytoplasmic dot-like expression
pattern reﬂecting an ALK-positive polyhedral coat on the
surface of vesciles [38]. Finally two other translocations,
the t(2;17)(p23;q25) and the t(2;22)(p23;q11.2), lead to
the translation of AL017- and MYH9-ALK chimera which
localized within the cytoplasms. A diﬀerent cell localiza-
tion is documented for the moesin- (MSN-) ALK fusion
protein, whose restricted surface membrane distribution is
probablyattributabletoassociationwithwild-typeMSNand
other membrane proteins. MSN-ALK does not contain an
oligomerization domain in its N-terminal domain.
Despite diﬀerent structural and cellular localization
all ALK fusion proteins have very similar transforming
properties in vitro and no clear clinical diﬀerences have been
so far described.
Together, these ﬁndings tend to suggest that the trans-
forming properties of ALK fusion could be due to their
cytoplamic localization and/or to activation of multiple
downstream molecules primarily localized within the cyto-
plasmic compartment.
5. ClinicalBehavior
ALCL is an aggressive lymphoma which frequently presents
in advanced clinical stage (III-IV) with systemic symptoms,
and extranodal involvement, as other PTCLs do [15, 60].
Bone marrow involvement is detected in up to 30% of cases,
being a relevant prognostic feature [71–73].
Importantly, ALCLs display quite diﬀerent clinical fea-
tures depending on the expression of the ALK protein [6,
15, 60, 74–76]. In particular, ALK+ tumors most frequently
occur among patients in the ﬁrst or second decade of life,
while ALK− ones are usually recorded among people aged
50–70 [6, 15, 60]. Moreover, advanced-stage disease and
B symptoms are slightly more common in ALK+ ALCL
[6, 15]. Most importantly, several studies have shown that
ALK+ has a signiﬁcantly better outcome than ALK− ALCL.
In particular, up to 90% of ALK+ ALCLs achieve complete
remission (CR) by adopting standard antracyclin-containing
regimens, and 70%–80% of patients were actually cured [6,
15, 60, 74–76]. By contrast, only around 30%–50% of ALK−
cases obtain stable CR by the same therapies [6, 15, 60],
suggesting that more aggressive strategies including autol-
ogous or allogenic bone-marrow/stem cell transplantation
may be necessary [77] .I n t e r e s t i n g l y ,l e u k e m i cs p r e a ds e e m s
to represent a major exception to the favorable prognosis of
ALK+ ALCL [6, 15, 60, 72].
Noteworthy, the International T-cell lymphoma project
has recently reported that ALK+ and ALK− ALCL seem to
haveasimilarprognosis(intermsofbothFFSandOS),when
patients are stratiﬁed according to the clinical parameters
(i.e., age and/or stage). Grippingly, this would suggest a
prominent role for clinical factors in determining patients
outcome, rather than for biological components [6].
Notably, in the past years, it was suggested that the
distinction between ALK− ALCL and peripheral T-cell
lymphoma, not otherwise speciﬁed (PTCL/NOS), was of
limited clinical relevance, only age and the International
Prognostic Index (IPI) being of prognostic relevance in these
tumors [78]. Nevertheless, it was recently shown that clinical
diﬀerences do exist between the two entities. In particular, in
a large international study, a greater proportion of patients
with poor performance status and B symptoms, but a lower
frequency of bone marrow invasion, splenic involvement,
and thrombocytopenia, was observed with ALK− ALCL
as compared to PTCL/NOS [6]. Indeed, in this study,Advances in Hematology 7
ALK− ALCL showed an overall outcome signiﬁcantly better
than PTCL/NOS [6].
6.TargetedTherapy
Despite the recent signiﬁcant progresses in understand-
ing the molecular pathogenesis of ALCL, the therapeu-
tic approaches are still based on doxorubicin-containing
combination chemotherapy [6]. However, the fact that
NPM-ALK plays a central role in the development and
progression of ALK+ ALCL tumors makes it an ideal
candidate therapeutic target in this disease. Notably, the
wt ALK protein is not widely expressed in adult tissues,
being abundant only in a few neuronal cells. Therefore, few
toxic eﬀects might be expected from treatment aimed at
blocking ALK function. Remarkably, the administration of
selectiveinhibitorsinducedtumorgrowtharrestandpossibly
its regression in vivo [79, 80]. More recently, ALK was
shown to be an ideal candidate target for antitumor vac-
cination. Indeed, in ALCL xenograft models, such strategy
completely prevented tumor growth and increased the per-
centages of cured mice when combined with chemotherapy
[42].
Additionally,theJAK/STATandthePI3K/AKThavebeen
recently proposed as potential targets in ALK+ lymphomas
[46, 81, 82]. Similarly, the blockage of their activation by
interfering with the upstream cytokines and growth factors
has been shown to be potentially eﬀective [83]. Importantly,
as tyrosine-kinase deregulation has been documented in
several other T-NHLs [68, 84–86], it is conceivable that
ALK− ALCL might present similar phenomenon as well,
further studies being indeed warranted.
Finally, immunotherapy strategies could represent
another possible therapeutic approaches. In particular, in
vitro and in vivo studies showed that antiCD30 antibodies
induce apoptotic cell death and tumor regression in
CD30+ lymphomas, including ALCL [87–91]. In addition,
other studies have suggested that CD26 might represent a
promising immunotherapeutic target [92].
7. Conclusion
In conclusion, based on the most recent ﬁndings, the WHO
classiﬁcation currently considers two ALCL types, ALK+
and ALK−. In fact, though the latter is still quoted as
a provisional entity, increasing evidence, both biological
and clinical, suggests the real existence of two distinct,
though similar, tumors. ALK represents an ideal therapeutic
target for innovative strategies, including small inhibiting
molecules and even vaccination. On the other hand, ALK−
cases may beneﬁt, in the future, from monoclonal antibodies
(i.e., antiCD30), tyrosine-kinase inhibitors, or other signal
transduction inhibitors.
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